Repligen Corporation (RGEN) Fair Value 2026

RGEN · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.0 /10

32 fundamental signals · 10 models active

Value Trap Risk

LOW (31/100)

Quick Summary — As of 2026-08-28, Repligen Corporation (RGEN) trades at $176.27, versus a $36.60 median fair value across its 10 active models — 79.2% below the current price. QOC: 8.0/10. Value Trap Risk: 31/100 (LOW). 10/13 models active. Within that set, the Bayesian DCF component alone returns $36.30.

Key Facts

Ticker
RGEN
Price
$176.27
Quality Score
8.0/10
Value Trap Risk
31/100
Models Active
10/13
Last Updated
Strength: Quality Score of 8.0/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is Repligen Corporation (RGEN) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Repligen Corporation (RGEN) appears overvalued as of : the median of 10 independent fair value estimates is $36.60, 79.2% below the current price of $176.27. Estimates range from $7.83 to $93.40. RGEN scores 8.0/10 on fundamental quality and 31/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. RGEN’s -79.2% gap is wider than that market norm, and the Medical Instruments & Supplies sector median is -29.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Repligen Corporation Stock in 2026? →

What Fair Value Does Each Model Give RGEN?

10 Intrinsic Value Models vs. Current Price ($176.27)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $36.30 -79.4%
Intrinsic · High Conviction
 $12.70 -92.8%
Ensemble · Low Conviction
 $36.90 -79.1%
Scenario · High Conviction
 $61.94 -64.9%
Unlock the Full Matrix

Access 6 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is RGEN's Fair Value Range?

Spread across 10 independent models · $7.83 to $93.40

CirclFi's 10 active models place Repligen Corporation (RGEN) between $7.83 and $93.40 per share, a spread of 234% of the median. The median of that range — $36.60 — is the fair value CirclFi publishes for RGEN, against a current price of $176.27.

Low · ML-RIVHigh · Regime Cross
$7.83median $36.60$93.40
Where the range comes from
Most bearish modelML Residual Income$7.83
Most bullish modelRegime Cross-Sectional$93.40
Model agreement0 bullish · 10 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for RGEN. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on RGEN, not a CirclFi price target. How each model works →

What Is Repligen Corporation (RGEN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Repligen Corporation's intrinsic value is estimated at $36.60. Trading at its current price of $176.27, the valuation engine raises significant caution: 10 of 10 models flag downside risk, projecting a median implied return of -79.2%. The most optimistic model, Regime Cross, places fair value at $93.40 (-47.0%), while ML-RIV — the most conservative — estimates $7.83 (-95.6%). This +48.5% gap reflects genuine analytical uncertainty about Repligen Corporation's intrinsic worth.

What Do the Models Say About RGEN?

10 of 13 models are currently active for RGEN. All 10 active models suggest the stock trades above fair value. Taken together, their median fair value for RGEN is $36.60 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $36.30 on its own, implying -79.4% downside from the current price. See which stocks rank higher →

How Does RGEN Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, RGEN ranks #13 by Quality of Company score. CirclFi's QOC score of 8.0/10 evaluates 32 fundamental signals. A score of 8.0 places RGEN in the top tier.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Repligen Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is RGEN a Value Trap?

CirclFi's Value Trap algorithm assigns RGEN a score of 31/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Repligen Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Repligen Corporation scores 8.0 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +48.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RGEN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RGEN's 10 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Repligen Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

UTMDUtah Medical Products, Inc.QOC 8.2EMBCEmbecta Corp.QOC 7.8NVSTEnvista Holdings CorporationQOC 8.3PDEXPro-Dex, Inc.QOC 7.8BDXBecton, Dickinson and CompanyQOC 8.3ATRCAtriCure, Inc.QOC 7.8OSUROraSure Technologies, Inc.QOC 6.8BNGOBionano Genomics, Inc.QOC 5.8ALCAlcon Inc.QOC 2.7ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: UTMD · EMBC · NVST · PDEX · BDX · ATRC · OSUR · BNGO · ALC · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to RGEN?

7 companies across all industries closest to RGEN’s Quality of Company score of 8.0/10.

FANGDiamondback Energy, Inc.QOC 8.0LNWOLight & Wonder, Inc.QOC 8.0PHINPHINIA Inc.QOC 8.0SSTKShutterstock, Inc.QOC 8.0GRANGrande Group LimitedQOC 8.0BWABorgWarner Inc.QOC 8.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FANG · LNWO · PHIN · SSTK · GRAN · BWA · NVDA

Where Does RGEN Sit in CirclFi's Medical Instruments & Supplies Rankings?

RGEN is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Repligen Corporation’s Valuation?

What is Repligen Corporation's intrinsic value in 2026?

CirclFi puts Repligen Corporation (RGEN)'s intrinsic value at $36.60 — the median of 10 independent model estimates as of 2026-08-28, ranging from $7.83 to $93.40. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $36.30 on its own. The Quality of Company score is 8.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RGEN overvalued or undervalued right now?

At $176.27, 0 of 10 active models suggest RGEN may be undervalued, while 10 indicate potential overvaluation. The median of all 10 fair value estimates is $36.60, 79.2% below the current price of $176.27 — a consensus view that RGEN is overvalued. The assessment depends on which methodology best fits Repligen Corporation's business model in Medical Instruments & Supplies.

What does a Quality of Company score of 8.0 mean for RGEN?

Repligen Corporation's QOC of 8.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on RGEN?

CirclFi analyzes RGEN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on RGEN?

Of the 10 models currently active on RGEN, Regime Cross-Sectional is the most bullish at $93.40 per share, and ML Residual Income is the most bearish at $7.83. CirclFi's published fair value for RGEN is the median of that range, $36.60, not either extreme. The gap between the two ends equals 234% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is RGEN a value trap in 2026?

Repligen Corporation's Value Trap score is 31/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Repligen Corporation (RGEN) has a median fair value of $36.60 — 79.2% below the current price of $176.27 — as of 2026-08-28.” Source: circlfi.com/stock/RGEN/ · Methodology
Primary sources for this RGEN valuation
  • Financial statements: Repligen Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000730272) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RGEN as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on RGEN.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

6 models hidden for RGEN Unlock All 10 — $39/mo